Strongbridge Biopharma (Strongbridge Biopharma) Total Inventories : $1.10 Mil (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Total Inventories?

Strongbridge Biopharma's total inventories for the quarter that ended in Jun. 2021 was $1.10 Mil. Strongbridge Biopharma's average total inventories from the quarter that ended in Mar. 2021 to the quarter that ended in Jun. 2021 was $1.05 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Strongbridge Biopharma's Net-Net Working Capital per share for the quarter that ended in Jun. 2021 was $0.22.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Strongbridge Biopharma's Days Inventory for the three months ended in Jun. 2021 was 205.95.

Inventory Turnover measures how fast the company turns over its inventory within a year. Strongbridge Biopharma's Inventory Turnover for the quarter that ended in Jun. 2021 was 0.44.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Strongbridge Biopharma's Inventory-to-Revenue for the quarter that ended in Jun. 2021 was 0.10.

Strongbridge Biopharma Total Inventories Historical Data

The historical data trend for Strongbridge Biopharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strongbridge Biopharma Total Inventories Chart

Strongbridge Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Inventories

Get a 7-Day Free Trial

0.51

3.95

1.99

1.10

Strongbridge Biopharma Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Total Inventories	Get a 7-Day Free Trial															1.32	1.12	1.10	1.01	1.10

Strongbridge Biopharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Strongbridge Biopharma (NAS:SBBP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Strongbridge Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2021 is

	Net-Net Working Capital Per Share (Q: Jun. 2021 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(63.774	+	0.75 * 3.581	+	0.5 * 1.101	-	52.429
-	0	-	0)	/	67.7223
=	0.22

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Strongbridge Biopharma's Days Inventory for the three months ended in Jun. 2021 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2021 )	/	Cost of Goods Sold (Q: Jun. 2021 )	*	Days in Period
	=	1.054	/	0.467	*	365 / 4
	=	205.95

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Strongbridge Biopharma's Inventory Turnover for the quarter that ended in Jun. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2021 )	/	Average Total Inventories (Q: Jun. 2021 )
	=	0.467	/	1.054
	=	0.44

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Strongbridge Biopharma's Inventory to Revenue for the quarter that ended in Jun. 2021 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2021 )	/	Revenue (Q: Jun. 2021 )
	=	1.054	/	10.042
	=	0.10

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Strongbridge Biopharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053

Website

http://www.strongbridgebio.com

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Executives

David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c.	10 percent owner	C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner	10 percent owner	C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp	10 percent owner	731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen	director	60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger	director	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long	officer: Chief Legal Officer	C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen	officer: Chief Medical Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit	officer: Chief Commercial Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz	officer: Chief Financial Officer	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender	officer: Chief Operating Officer	C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380